In addition, treatment with PEGV-200 significantly decreased HCC cell proliferation, measured by Ki-67 proliferation index, in HepG2 and HepG2-SR tumor xenografts (Figures 6E, F). This evidence concerns the gene MKI67 and hepatocellular carcinoma.